RNAC FY 2021 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$85M+412.6% YoY

Gross Profit

$85M100.0% margin

Operating Income

-$5M-5.4% margin

Net Income

-$26M-30.2% margin

EPS (Diluted)

$-6.60

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$61M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$160M

Total Liabilities

$137M

Stockholders' Equity

$23M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$17M	+412.6%
Gross Profit	$85M	$17M	+412.6%
Operating Income	-$5M	-$57M	+91.9%
Net Income	-$26M	-$69M	+62.7%